BACKGROUND: This study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 ((90)Y) ibritumomab tiuxetan combined with the etoposide rabinoside acytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low-grade B-cell lymphomas. PATIENTS AND METHODS: From March 2005 to August 2006, 77 prospective patients were included, 69 (90%) with follicular lymphomas. RESULTS: The last salvage chemotherapy regimen included rituximab for 74 patients and ASCT for 75 patients. Before ASCT, rates of complete response/unconfirmed response (CR/CRu) and partial response were 77% and 23%, respectively. After zevaline-BEAM (Z-BEAM), time to >1 × 10(9)/L neutrophils was 12 days (range, 9-35 days), and time to >20 × 10(9)/L platelets was 12 days (range, 3-42 days). No other significant extrahematologic toxicity was observed. Three months after ASCT, 68 patients (88%) were in CR/CRu. After a median follow-up of 28 months, 2-year event-free survival (EFS) and overall survival were 63% and 97%, respectively, but EFS for first-relapsed patients was 72%. When using patients as their own controls, 2-year EFS was superior after ASCT and compared favorably with the duration of response of last chemotherapy (62% vs. 37%, P = .007) (Point 1.10). CONCLUSION: Z-BEAM appears safe and needs to be further evaluated in a randomized trial. 2011. Published by Elsevier Inc.
BACKGROUND: This study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 ((90)Y) ibritumomab tiuxetan combined with the etoposide rabinosideacytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low-grade B-cell lymphomas. PATIENTS AND METHODS: From March 2005 to August 2006, 77 prospective patients were included, 69 (90%) with follicular lymphomas. RESULTS: The last salvage chemotherapy regimen included rituximab for 74 patients and ASCT for 75 patients. Before ASCT, rates of complete response/unconfirmed response (CR/CRu) and partial response were 77% and 23%, respectively. After zevaline-BEAM (Z-BEAM), time to >1 × 10(9)/L neutrophils was 12 days (range, 9-35 days), and time to >20 × 10(9)/L platelets was 12 days (range, 3-42 days). No other significant extrahematologic toxicity was observed. Three months after ASCT, 68 patients (88%) were in CR/CRu. After a median follow-up of 28 months, 2-year event-free survival (EFS) and overall survival were 63% and 97%, respectively, but EFS for first-relapsed patients was 72%. When using patients as their own controls, 2-year EFS was superior after ASCT and compared favorably with the duration of response of last chemotherapy (62% vs. 37%, P = .007) (Point 1.10). CONCLUSION: Z-BEAM appears safe and needs to be further evaluated in a randomized trial. 2011. Published by Elsevier Inc.
Authors: Amrita Y Krishnan; Joycelynne Palmer; Auayporn P Nademanee; Robert Chen; Leslie L Popplewell; Ni-Chun Tsai; James F Sanchez; Jennifer Simpson; Ricardo Spielberger; Dave Yamauchi; Stephen J Forman Journal: Biol Blood Marrow Transplant Date: 2017-03-04 Impact factor: 5.742
Authors: L Bento; A Boumendil; H Finel; S Le Gouill; S Amorim; H Monjanel; R Bouabdallah; J O Bay; E Nicolas-Virelizier; G McQuaker; G Rossi; R Johnson; A Huynh; P Ceballos; A Rambaldi; E Bachy; R Malladi; K Orchard; D Pohlreich; H Tilly; F Bonifazi; X Poiré; F Guilhot; A Haenel; C Crawley; B Metzner; J Gribben; N H Russell; G Damaj; K Thomson; P Dreger; S Montoto Journal: Bone Marrow Transplant Date: 2017-05-22 Impact factor: 5.483
Authors: L Philippe; P Helias; M Puyraveau; H Boulahdour; E Deconinck; E Daguindau Journal: Bone Marrow Transplant Date: 2016-04-04 Impact factor: 5.483
Authors: Julie M Vose; Shelly Carter; Linda J Burns; Ernesto Ayala; Oliver W Press; Craig H Moskowitz; Edward A Stadtmauer; Shin Mineshi; Richard Ambinder; Timothy Fenske; Mary Horowitz; Richard Fisher; Marcie Tomblyn Journal: J Clin Oncol Date: 2013-03-11 Impact factor: 44.544
Authors: Karin Hohloch; H K Lankeit; P L Zinzani; C W Scholz; M Lorsbach; C Windemuth-Kieselbach; L Trümper Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-11 Impact factor: 9.236